TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Current Deferred Revenue data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 84.06% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 84.06% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, down 77.61% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $1.6 million, down from $2.6 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for TCRX reached as high as $19.2 million in Q2 2023 and fell as low as $1.6 million in Q1 2026.
• Historically, Current Deferred Revenue has averaged $9.0 million across 5 years, with a median of $10.0 million in 2023.
• Across the five-year window, Current Deferred Revenue surged 161.67% in 2023 and plunged 84.06% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $3.9 million in 2022, then soared by 161.67% to $10.1 million in 2023, then climbed by 15.4% to $11.7 million in 2024, then plunged by 77.61% to $2.6 million in 2025, then tumbled by 37.5% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $1.6 million in Q1 2026, $2.6 million in Q4 2025, and $5.2 million in Q3 2025.